2024-10-24 – Press Releases – www.prnewswire.com
PROVIDENCE, R.I., Oct. 24, 2024 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) and CUBRC, Inc. (“CUBRC”) announce today that they have been awarded a two-year, $2 million contract (#75F40124C00094) from the Office of Generic Drugs (OGD) of the Food and Drug Administration (FDA) to develop…